|
"vogel a"的相关文件
显示项目 1-25 / 29 (共2页)
1 2 > >>
每页显示[10|25|50]项目
| 國家衛生研究院 |
2023-09-25 |
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
|
Oh, DY;He, AR;Qin, SK;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, H;Bouattour, M;Tanasanvimon, S;McNamara, MG;Zaucha, R;Avallone, A;Tan, BJM;Cundom, J;Lee, CK;Takahashi, H;Ikeda, M;Chen, JS;Wang, JL;Makowsky, M;Rokutanda, N;Zotkiewicz, M;Kurland, JF;Cohen, G;Valle, JW |
| 國家衛生研究院 |
2023-03-31 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) [Erratum:Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462
|
Oh, D;He, AR;Qin, S;Chen, L;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasa, S;Zaucha, RE;Avallone, A;Cundom, JE;Rokutanda, N;Żotkiewicz, M;Cohen, G;Valle, JW |
| 國家衛生研究院 |
2022-11 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Lee, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, RE;Avallone, A;Cundom, JE;Rokutanda, N;Zotkiewicz, M;Cohen, G;Valle, JW |
| 國家衛生研究院 |
2022-09 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, RE;Avallone, A;Cundom, JE;Rokutanda, N;Watras, M;Cohen, G;Valle, JW |
| 臺大學術典藏 |
2022-08-19T00:20:34Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Douillard J.-Y.; Yoshino T.; Yen Y.; Hsu C.-H.; Tabernero J.; Shen Y.-C.; CHIUN HSU; Chen S.-C.; Huang Y.-H.; Yen C.-J.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Pentheroudakis G.; Cheng A.-L.; Chen L.-T.; Martinelli E. |
| 臺大學術典藏 |
2022-08-19T00:20:31Z |
Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab
|
CHIUN HSU; Rimassa L.; Sun H.-C.; Vogel A.; Kaseb A.O. |
| 臺大學術典藏 |
2022-02-21T02:04:32Z |
Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: From the phase III REFLECT study
|
Finn R.S.; Kudo M.; ANN-LII CHENG; Wyrwicz L.; Ngan R.K.C.; Blanc J.-F.; Baron A.D.; Vogel A.; Ikeda M.; Piscaglia F.; Han K.-H.; Qin S.; Minoshima Y.; Kanekiyo M.; Ren M.; Dairiki R.; Tamai T.; Dutcus C.E.; Ikezawa H.; Funahashi Y.; Evans T.R.J. |
| 國家衛生研究院 |
2022-02-01 |
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, R;Avallone, A;Cundom, J;Rokutanda, N;Xiong, J;Cohen, G;Valle, JW |
| 國立成功大學 |
2022 |
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
|
Chan, S.L.;Schuler, M.;Kang, Y.-K.;Yen, C.-J.;Edeline, J.;Choo, S.P.;Lin, C.-C.;Okusaka, T.;Weiss, K.-H.;Macarulla, T.;Cattan, S.;Blanc, J.-F.;Lee, K.-H.;Maur, Maur M.;Pant, S.;Kudo, M.;Assenat, E.;Zhu, A.X.;Yau, T.;Lim, H.Y.;Bruix, J.;Geier, A.;Guill�n-Ponce, C.;Fasolo, A.;Finn, R.S.;Fan, J.;Vogel, A.;Qin, S.;Riester, M.;Katsanou, V.;Chaudhari, M.;Kakizume, T.;Gu, Y.;Porta, D.G.;Myers, A.;Delord, J.-P. |
| 國家衛生研究院 |
2021-10 |
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: A randomised, double-blind, multicentre, phase 2 study
|
Valle, JW;Vogel, A;Denlinger, CS;He, AR;Bai, LY;Orlova, R;Van Cutsem, E;Adeva, J;Chen, LT;Obermannova, R;Ettrich, TJ;Chen, JS;Wasan, H;Girvan, AC;Zhang, W;Liu, JG;Tang, CL;Ebert, PJ;Aggarwal, A;McNeely, SC;Moser, BA;Oliveira, JM;Carlesi, R;Walgren, RA;Oh, DY |
| 臺大學術典藏 |
2021-08-31T06:29:30Z |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
|
Kudo M.; Finn R.S.; Qin S.; Han K.-H.; Ikeda K.; Piscaglia F.; Baron A.; Park J.-W.; Han G.; Jassem J.; Blanc J.F.; Vogel A.; Komov D.; Evans T.R.J.; Lopez C.; Dutcus C.; Guo M.; Saito K.; Kraljevic S.; Tamai T.; Ren M.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-08-31T06:29:28Z |
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYnote-224): a non-randomised, open-label phase 2 trial
|
Zhu A.X.; Finn R.S.; Edeline J.; Cattan S.; Ogasawara S.; Palmer D.; Verslype C.; Zagonel V.; Fartoux L.; Vogel A.; Sarker D.; Verset G.; Chan S.L.; Knox J.; Daniele B.; Webber A.L.; Ebbinghaus S.W.; Ma J.; Siegel A.B.; ANN-LII CHENG; Kudo M.; Alistar A.; Asselah J.; Blanc J.-F.; Borbath I.; Cannon T.; Chung K.; Cohn A.; Cosgrove D.P.; Damjanov N.; Gupta M.; Karino Y.; Karwal M.; Kaubisch A.; Kelley R.; Van Laethem J.-L.; Larson T.; Lee J.; Li D.; Manhas A.; Manji G.A.; Numata K.; Parsons B.; Paulson A.S.; Pinto C.; Ramirez R.; Ratnam S.; Rizell M.; Rosmorduc O.; Sada Y.; Sasaki Y.; Stal P.I.; Strasser S.; Trojan J.; Vaccaro G.; Van Vlierberghe H.; Weiss A.; Weiss K.-H.; Yamashita T.; KEYnote-224 investigators |
| 臺大學術典藏 |
2021-08-31T06:29:20Z |
Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma
|
Alsina A.; Kudo M.; Vogel A.; ANN-LII CHENG; Tak W.Y.; Ryoo B.-Y.; Evans T.R.J.; L?pez L?pez C.; Daniele B.; Misir S.; Ren M.; Izumi N.; Qin S.; Finn R.S. |
| 臺大學術典藏 |
2021-08-31T06:29:18Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.; Martinelli E.; ANN-LII CHENG; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Shen Y.-C.; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-03-09T05:18:30Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.; Martinelli E.; Cheng A.-L.; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Hsu C.; Ying-Chun Shen; Tabernero J.; Yen Y.; Hsu C.-H.; Yoshino T.; Douillard J.-Y. |
| 臺大學術典藏 |
2021-02-19T06:52:26Z |
Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies
|
Yen C.-J.;Kudo M.;Lim H.-Y.;Chih-Hung Hsu;Vogel A.;Brandi G.;Cheng R.;Nitu I.S.;Abada P.;Hsu Y.;Zhu A.X.;Kang Y.-K.; Yen C.-J.; Kudo M.; Lim H.-Y.; CHIH-HUNG HSU; Vogel A.; Brandi G.; Cheng R.; Nitu I.S.; Abada P.; Hsu Y.; Zhu A.X.; Kang Y.-K. |
| 臺大學術典藏 |
2021-02-19T06:52:25Z |
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
|
Zhu A.X.;Finn R.S.;Kang Y.-K.;Yen C.-J.;Galle P.R.;Llovet J.M.;Assenat E.;Brandi G.;Motomura K.;Ohno I.;Daniele B.;Vogel A.;Yamashita T.;Chih-Hung Hsu;Gerken G.;Bilbruck J.;Hsu Y.;Liang K.;Widau R.C.;Wang C.;Abada P.;Kudo M.; Zhu A.X.; Finn R.S.; Kang Y.-K.; Yen C.-J.; Galle P.R.; Llovet J.M.; Assenat E.; Brandi G.; Motomura K.; Ohno I.; Daniele B.; Vogel A.; Yamashita T.; CHIH-HUNG HSU; Gerken G.; Bilbruck J.; Hsu Y.; Liang K.; Widau R.C.; Wang C.; Abada P.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T02:33:47Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS�VESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen L.-T.;Martinelli E.;Cheng A.-L.;Pentheroudakis G.;Qin S.;Bhattacharyya G.S.;Ikeda M.;Lim H.-Y.;Ho G.F.;Choo S.P.;Ren Z.;Malhotra H.;Ueno M.;Ryoo B.-Y.;Kiang T.C.;Tai D.;Vogel A.;Cervantes A.;Lu S.-N.;Yen C.-J.;Huang Y.-H.;Chen S.-C.;Shen Y.-C.;Tabernero J.;Yen Y.;Chiun Hsu;Yoshino T.;Douillard J.-Y.; Chen L.-T.; Martinelli E.; Cheng A.-L.; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Shen Y.-C.; Tabernero J.; Yen Y.; Chiun Hsu; Yoshino T.; Douillard J.-Y. |
| 國立成功大學 |
2021 |
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
|
Kudo, M.;Galle, P.R.;Brandi, G.;Kang, Y.-K.;Yen, C.-J.;Finn, R.S.;Llovet, J.M.;Assenat, E.;Merle, P.;Chan, S.L.;Palmer, D.H.;Ikeda, M.;Yamashita, T.;Vogel, A.;Huang, Y.-H.;Abada, P.B.;Yoshikawa, R.;Shinozaki, K.;Wang, C.;Widau, R.C.;Zhu, A.X. |
| 國立成功大學 |
2021 |
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
|
Zhu, A.X.;Finn, R.S.;Kang, Y.-K.;Yen, C.-J.;Galle, P.R.;Llovet, J.M.;Assenat, E.;Brandi, G.;Motomura, K.;Ohno, I.;Daniele, B.;Vogel, A.;Yamashita, T.;Hsu, C.-H.;Gerken, Gerken G.;Bilbruck, J.;Hsu, Y.;Liang, K.;Widau, R.C.;Wang, C.;Abada, P.;Kudo, M. |
| 國家衛生研究院 |
2020-03 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: A TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen, LT;Martinelli, E;Cheng, AL;Pentheroudakis, G;Qin, S;Bhattacharyya, GS;Ikeda, M;Lim, HY;Ho, GF;Choo, SP;Ren, Z;Malhotra, H;Ueno, M;Ryoo, BY;Kiang, TC;Tai, D;Vogel, A;Cervantes, A;Lu, SN;Yen, CJ;Huang, YH;Chen, SC;Hsu, C;Shen, YC;Tabernero, J;Yen, Y;Hsu, CH;Yoshino, T;Douillard, JY |
| 國家衛生研究院 |
2020-02 |
Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study
|
Valle, JW;Bai, LY;Orlova, R;Van Cutsem, E;Alfonso, JA;Chen, LT;Obermannova, R;Ettrich, TJ;Chen, JS;Wasan, HS;Denlinger, CS;Vogel, A;He, AR;Bousmans, N;Girvan, AC;Zhang, W;Walgren, RA;Carlesi, R;Oh, DY |
| 臺大學術典藏 |
2020 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Douillard J.-Y.; Yoshino T.; CHIH-HUNG HSU; Yen Y.; Tabernero J.; Shen Y.-C.; Hsu C.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; Cheng A.-L.; Martinelli E.; Chen L.-T.; Chen L.-T.;Martinelli E.;Cheng A.-L.;Pentheroudakis G.;Qin S.;Bhattacharyya G.S.;Ikeda M.;Lim H.-Y.;Ho G.F.;Choo S.P.;Ren Z.;Malhotra H.;Ueno M.;Ryoo B.-Y.;Kiang T.C.;Tai D.;Vogel A.;Cervantes A.;Lu S.-N.;Yen C.-J.;Huang Y.-H.;Chen S.-C.;Hsu C.;Shen Y.-C.;Tabernero J.;Yen Y.;Chih-Hung Hsu;Yoshino T.;Douillard J.-Y.; Choo S.P.; Ho G.F.; Lim H.-Y.; Ikeda M.; Bhattacharyya G.S.; Qin S.; Pentheroudakis G. |
| 國立成功大學 |
2020 |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
|
Chen, L.-T.;Martinelli, E.;Cheng, A.-L.;Pentheroudakis, G.;Qin, S.;Bhattacharyya, G.S.;Ikeda, M.;Lim, H.-Y.;Ho, G.F.;Choo, S.P.;Ren, Z.;Malhotra, H.;Ueno, M.;Ryoo, B.-Y.;Kiang, T.C.;Tai, D.;Vogel, A.;Cervantes, A.;Lu, S.-N.;Yen, C.-J.;Huang, Y.-H.;Chen, S.-C.;Hsu, C.;Shen, Y.-C.;Tabernero, J.;Yen, Yen Y.;Hsu, C.-H.;Yoshino, T.;Douillard, J.-Y. |
| 國立成功大學 |
2020 |
Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies
|
Yen, C.-J.;Kudo, M.;Lim, H.-Y.;Hsu, C.-H.;Vogel, A.;Brandi, G.;Cheng, R.;Nitu, I.S.;Abada, P.;Hsu, Y.;Zhu, A.X.;Kang, Y.-K. |
显示项目 1-25 / 29 (共2页)
1 2 > >>
每页显示[10|25|50]项目
|
